© 2020 MJH Life Sciences and Urology Times. All rights reserved.
© 2020 MJH Life Sciences™ and Urology Times. All rights reserved.
September 24, 2020
The positive findings could make nivolumab the new standard of care in the adjuvant setting for patients with muscle-invasive urothelial cancer.
The antibody-drug conjugate enfortumab vedotin significantly improved overall survival versus chemotherapy in a phase 3 trial.
September 23, 2020
Pivotal phase 3 trial launched to confirm promising results in metastatic urothelial carcinoma.
September 17, 2020
Of 2463 patients with urothelial cancer who underwent comprehensive genomic profiling, 39% harbored ≥1 tier 1-2 genomic alterations.
September 14, 2020
“The grasper disposable scope may fill the gap as an alternative to the conventional reusable cystoscope,” researchers concluded.
Tele-cystoscopy was found equivalent to traditional cystoscopy with respect to identification of abnormalities and action decisions.
August 26, 2020
Differences following surgery were related to the control of cancer and adjustments with urinary diversion.
August 25, 2020
"Therapeutic strategies are needed in the management of NMIBC that recurs after gold-standard intravesical BCG," Gomella writes.
August 20, 2020
Investigators warn of the dangers of overprescribing antibiotics in cancer care.
August 18, 2020
The new dose would reduce a patient’s required medical visits by 50%.
August 14, 2020
Increased usage of bladder diagrams was observed following implementation of the program.
August 07, 2020
Including the genomic test in the protocol for patient surveillance reduced the average number of annual cystoscopies by approximately 39%.
August 04, 2020
The cost-savings are particularly noteworthy given prior evidence of blue light imaging enhancing the efficacy of diagnostic cystoscopy.
July 31, 2020
A multidisciplinary panel outlines criteria for stratifying risk for genitourinary malignancy in patients with microhematuria.
July 24, 2020
Intravesical Oncofid P-B, a conjugate of paclitaxel and hyaluronic acid, is active in patients with carcinoma in situ of the bladder that is not responsive to bacillus Calmette-Guérin.
Given the efficacy and safety demonstrated, there may be a role going forward for the pembrolizumab/nab-paclitaxel combination in earlier disease stages.
July 17, 2020
Intravesical instillations prevent recurrence of non–muscle-invasive bladder cancer.
July 15, 2020
The study compared regimens for patients with high-risk non–muscle invasive bladder cancer.
July 14, 2020
72.9% of patients with papillary disease achieved high-grade recurrence-free survival at 3 months after initial treatment.
July 08, 2020
Cabozantinib's single-agent activity opens the potential for combination approaches with immunotherapy in patients with heavily pretreated urothelial carcinoma.